Novel 3-trifluoromethyl-1,2,4-oxadiazole analogues of astemizole with multi-stage antiplasmodium activity and in vivo efficacy in a Plasmodium berghei mouse malaria infection model

Mambwe, DicksonKorkor, Constance M.Mabhula, AmandaNgqumba, ZamaCloete, CleavonKumar, MalkeetBarros, Paula LadeiaLeshabane, Meta KgaogeloCoertzen, DinaTaylor, DaleGibhard, LiezlNjoroge, MathewLawrence, NinaReader, JanetteMoreira, Diogo RodrigoBirkholtz, Lyn-MarieWittlin, SergioEgan, Timothy J.Chibale, Kelly2023-02-242022-12Mambwe, D., Korkor, C.M., Mabhula, A. et al. 2022, 'Novel 3-trifluoromethyl-1,2,4-oxadiazole analogues of astemizole with multi-stage antiplasmodium activity and in vivo efficacy in a Plasmodium berghei mouse malaria infection model', Journal of Medicinal Chemistry, vol. 65, no. 24, pp. 16695–16715, doi : 10.1021/acs.jmedchem.2c01516.0022-2623 (print)1520-4804 (online)10.1021/acs.jmedchem.2c01516https://repository.up.ac.za/handle/2263/89809Please read abstract in the article.enThis document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, © 2022 American Chemical Society after peer review and technical editing by the publisher. [12 months embargo]AstemizoleRepositioningPlasmodium falciparumPlasmodium bergheiHuman ether-á-go-go-related gene (hERG)Live-cell microscopyNovel 3-trifluoromethyl-1,2,4-oxadiazole analogues of astemizole with multi-stage antiplasmodium activity and in vivo efficacy in a Plasmodium berghei mouse malaria infection modelPostprint Article